All Articles
Final results from the LYRA study demonstrate daratumumab plus cyclophosphamide, bortezomib, dexamethasone was well-tolerated and effective in patients with newly diagnosed or relapsed/refractory multiple myeloma. Read More ›
Patient and caregiver preferences are important factors in selecting treatments. Read More ›
Better understanding of physician decision factors when selecting therapy for patients with refractory multiple myeloma may facilitate adoption of a wider variety of new treatment options. Read More ›
Subanalysis strongly supports the use of isatuximab plus carfilzomib and dexamethasone regardless of prior lines of therapy or refractory status to lenalidomide and bortezomib. Read More ›
Integrating a pharmacist into the care team can have substantial clinical and financial benefits in the setting of relapsed/refractory multiple myeloma and anti-CD38 antibodies. Read More ›
Carfilzomib plus dexamethasone and daratumumab show improved responses compared with carfilzomib plus dexamethasone in patients with relapsed/refractory multiple myeloma regardless of cytogenetic risk. Read More ›
Dr Andrew Zelenetz presents key aspects of the epidemiology of, and currently achieved survivorship in, follicular lymphoma (FL) and compares them with those seen in more commonly diagnosed malignancies treated by the broader group of community-based medical oncologists. Dr Tycel Phillips comments on the paucity of patient features or disease attributes that would help predict poor clinical outcomes, including reduced survival, when FL patients are evaluated at the time of initial diagnosis. Read More ›
By William King
Targeting HER2 with the antibody–drug conjugate fam-trastuzumab deruxtecan-nxki (Enhertu; T-DXd) provided clinically meaningful benefits for patients with HER2-low metastatic breast cancer, according to findings presented at the 2022 American Society of Clinical Oncology Annual Meeting. Read More ›
We now know what will follow the Oncology Care Model (OCM). On June 27, 2022, the Centers for Medicare & Medicaid Services’ (CMS) Innovation Center announced the voluntary Enhancing Oncology Model (EOM). Read More ›
There are several methods that can be used to gain a better perspective when determining the success of an oncology practice and its operations. Financial evaluation, access to care, quality metrics, and employee engagement are just a few of the operational elements that are important to consider, especially as they relate to the overall patient experience. Read More ›